Wave Life Sciences Ltd [NASDAQ: WVE] traded at a high on 2025-12-08, posting a 147.26 gain after which it closed the day’ session at $18.52.
The results of the trading session contributed to over 145755483 shares changing hands. Over the past one week, the price volatility of Wave Life Sciences Ltd stands at 15.65% while the volatility over the past one month is 9.36%.
The market cap for WVE stock reached $3.10 billion, with 160.29 million shares outstanding and 134.97 million shares in the current float. Compared to the average trading volume of 2.59M shares, WVE reached a trading volume of 145755483 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Wave Life Sciences Ltd [WVE]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for WVE shares is $27.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on WVE stock is a recommendation set at 1.07. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Wave Life Sciences Ltd shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 20, 2025. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price to Buy. The new note on the price target was released on August 04, 2025, representing the official price target for Wave Life Sciences Ltd stock. Previously, the target price had yet another raise to $24, while Oppenheimer analysts kept a Outperform rating on WVE stock.
The Price to Book ratio for the last quarter was 23.83, with the Price to Cash per share for the same quarter was set at 1.17.
How has WVE stock performed recently?
Wave Life Sciences Ltd [WVE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 149.93. With this latest performance, WVE shares gained by 135.03% in over the last four-week period, additionally plugging by 162.70% over the last 6 months – not to mention a rise of 49.72% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for WVE stock in for the last two-week period is set at 88.69, with the RSI for the last a single of trading hit 1.74, and the three-weeks RSI is set at 1.07 for Wave Life Sciences Ltd [WVE]. The present Moving Average for the last 50 days of trading for this stock 7.72, while it was recorded at 9.55 for the last single week of trading, and 7.79 for the last 200 days.
Wave Life Sciences Ltd [WVE]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Wave Life Sciences Ltd [WVE] shares currently have an operating margin of -124.46% and a Gross Margin at 91.99%. Wave Life Sciences Ltd’s Net Margin is presently recorded at -111.64%.
Wave Life Sciences Ltd (WVE) Capital Structure & Debt Analysis
According to recent financial data for Wave Life Sciences Ltd. ( WVE), the Return on Equity (ROE) stands at -86.51%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -40.66%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Wave Life Sciences Ltd’s Return on Invested Capital (ROIC) is -84.80%, showcasing its effectiveness in deploying capital for earnings.
Wave Life Sciences Ltd (WVE) Efficiency & Liquidity Metrics
Based on Wave Life Sciences Ltd’s (WVE) latest financial statements, the Debt-to-Equity Ratio is 0.15%, indicating its reliance on debt financing relative to shareholder equity.
Wave Life Sciences Ltd (WVE) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Wave Life Sciences Ltd. (WVE) effectively leverages its workforce, generating an average of -$423437.5 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.51% and a Quick Ratio of 2.51%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Wave Life Sciences Ltd [WVE]
With the latest financial reports released by the company, Wave Life Sciences Ltd posted 0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.5. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for WVE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Wave Life Sciences Ltd go to -17.82%.
Insider trade positions for Wave Life Sciences Ltd [WVE]
There are presently around $86.00%, or 101.21%% of WVE stock, in the hands of institutional investors. The top three institutional holders of WVE stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 18.2 million shares, which is approximately 14.0527%. MAVERICK CAPITAL LTD, holding 7.67 million shares of the stock with an approximate value of $$38.27 million in WVE stocks shares; and MAVERICK CAPITAL LTD, currently with $$33.63 million in WVE stock with ownership which is approximately 5.2026%.
